Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

Immunic, Inc. Announces First Patients…

Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock

Immunic, Inc. Announces Pricing of…

Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients

Immunic, Inc. Receives First Regulatory…

Immunic, Inc. Announces Pricing of $15 Million Financing

Immunic, Inc. Announces Pricing of…

Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

Immunic, Inc. Reports that IMU-838,…

Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson

Immunic, Inc. Expands Board of…

Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

Immunic, Inc. Announces Completion of…

Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist

Immunic, Inc. Doses First Healthy…

Immunic, Inc.’s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range

Immunic, Inc.'s Interim Dosing Analysis…

Complete transaction creating Nasdaq-listed company targeting chronic inflammatory and autoimmune diseases

– Developing Oral Therapies with…